ArticlePatient preference and adherence2026
Respiratory Syncytial Virus (RSV) Vaccine Acceptance Among the Elderly in Al-Qassim Region, Saudi Arabia.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Respiratory Syncytial Virus (RSV) vaccine has recently been introduced in Saudi Arabia for adults aged 60 and older. There are limited published studies on this topic in Saudi Arabia for this age group. This study aimed to assess RSV vaccine acceptance among older adults in the Al-Qassim region of Saudi Arabia. Methods: The data were collected via online forms that invited participants aged 60 years and older, living in the Al-Qassim region, to participate. The study tool included items related to sociodemographic variables, chronic disease history, knowledge of the RSV disease, and perceived susceptibility and severity. In addition to previous RSV uptake and willingness to vaccinate, along with previous vaccination history for other indicated vaccines such as herpes zoster, Influenza, and Pneumococcal. Results: 341 responses met the inclusion criteria. The majority of participants were aged < 70 years (74.5%), males (57.5%), and 38.1% had a university education or higher. 67.7% had at least one chronic disease, with diabetes being the most common (41.8%). The majority (83.6%) have never heard of RSV. Only 5 (1.5%) respondents reported prior uptake, while 16.1% demonstrated RSV acceptance overall. The most prominent facilitator among vaccine-acceptant individuals was physician or healthcare professional recommendation (45.5%). The most cited barriers among vaccine-hesitant or undecided individuals (n=286) were the perception of the RSV vaccine as "a new vaccine" (50.0%) and concerns about vaccine safety and effectiveness (44.1% and 26.2%, respectively). Only higher uptake of other indicated vaccines showed a significant association with vaccine acceptance (aOR 1.575, 95% CI 1.220-2.033, p < 0.001). Conclusion: The study demonstrated very low vaccine uptake and willingness, with reported barriers like concerns about the vaccine's recent introduction and uncertainty about its safety and effectiveness. Efforts tailored to educate the elderly about the vaccine's importance, safety, and effectiveness are needed to improve vaccine uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.